Implications of Food and Drug Administration Approval of Respiratory Syncytial Virus Prophylactic Medication

Ashley L. Saint-Fleur; Catherine Kier

doi:10.1542/pir.2023-006246

Implications of Food and Drug Administration Approval of Respiratory Syncytial Virus Prophylactic Medication

Ashley L. Saint-Fleur
, Catherine Kier

Pediatrics

Boston Children's Hospital

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	723-724
Number of pages	2
Journal	Pediatrics in Review
Volume	44
Issue number	12
DOIs	https://doi.org/10.1542/pir.2023-006246
State	Published - Dec 1 2023

Access to Document

10.1542/pir.2023-006246

Cite this

@article{4d5d5e634ab641b0953ff207f19fe415,

title = "Implications of Food and Drug Administration Approval of Respiratory Syncytial Virus Prophylactic Medication",

author = "Saint-Fleur, \{Ashley L.\} and Catherine Kier",

year = "2023",

month = dec,

day = "1",

doi = "10.1542/pir.2023-006246",

language = "English",

volume = "44",

pages = "723--724",

journal = "Pediatrics in Review",

issn = "0191-9601",

number = "12",

}

TY - JOUR

T1 - Implications of Food and Drug Administration Approval of Respiratory Syncytial Virus Prophylactic Medication

AU - Saint-Fleur, Ashley L.

AU - Kier, Catherine

PY - 2023/12/1

Y1 - 2023/12/1

UR - https://www.scopus.com/pages/publications/85178501549

U2 - 10.1542/pir.2023-006246

DO - 10.1542/pir.2023-006246

M3 - Article

C2 - 37779223

AN - SCOPUS:85178501549

SN - 0191-9601

VL - 44

SP - 723

EP - 724

JO - Pediatrics in Review

JF - Pediatrics in Review

IS - 12

ER -

Implications of Food and Drug Administration Approval of Respiratory Syncytial Virus Prophylactic Medication

Access to Document

Other files and links

Fingerprint

Cite this